The company is still a decent buy, just don't rely on Acthar. Licensing of Synacthen should put a damper on revs, but I don't know if there is a timetable for that to occur.
Possibly MNK has something sneaky up their sleeve, quick to pay off the $100M fine which isn't all THAT much (10% of Acthar revenue). Maybe MNK just wanted to get FDA off their backs?
It will take time for recovery and the (somewhat) re-organzation towards the hospital field is very long-term positive. The other acquisitions will also offset Acthar diminishing returns if Synacthen is licensed.
Sarcasm mixed in with unknown timetables and social pressure. I personally don't want it to go lower.
I'm still long in this, no buys no sells since acq. Kind of bites my average shot up to $49.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.